Fig. 4: Effect of anti-Mstn treatment on tumor progression and body weight in a syngeneic 4T1 mouse model of BC metastases. | Oncogene

Fig. 4: Effect of anti-Mstn treatment on tumor progression and body weight in a syngeneic 4T1 mouse model of BC metastases.

From: Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models

Fig. 4: Effect of anti-Mstn treatment on tumor progression and body weight in a syngeneic 4T1 mouse model of BC metastases.

A Representative bioluminescence images of 4T1 luc2+ cells injected mice at the indicated time points from ventral (left) and dorsal (right) views. Quantitative evaluation of bioluminescence intensity in knee joints of 4T1 luc2 + -injected and vehicle (n = 9) or anti-Mstn treated mice (n = 7). B Representative H&E-staining of tibia from naïve Balb/c mice (healthy control) and mice injected with 4T1 luc2+ breast cancer cells (E = epiphysis, GP = growth plate, TC = tumor cell). C Effect of anti-Mstn treatment on body weight of 4T1 luc2 + -injected mice (vehicle: n = 7, anti-Mstn: n = 5). D Effect of anti-Mstn treatment on quadriceps femoris muscle weight of 4T1-injected mice (vehicle: n = 14, anti-Mstn: n = 10, left and right). Shown are individual data and mean values ± SEM, one-way ANOVA, Kruskal-Wallis test with multiple comparisons or Mann-Whitney test, two-tailed, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Back to article page